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Abstract A 44-year-old man suffering from cytogeneti-
cally and molecularly proven Philadelphia transloca-
tion-positive chronic myelogenous leukemia in chronic
phase was treated with busulfan for 18 months and
studied during a follow-up period of 13 years. Hemato-
logically and cytogenetically, he attained a continuing
complete remission, although at one point (9.5 years) at
least, after attaining complete remission molecular
analysis indicated the presence of minimal residual dis-
ease.
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Introduction
The clinical course of chronic myelogenous leukemia
(CML) is characterized by a chronic phase lasting for
an average of 3 years, followed by an accelerated phase
and a blastic transformation. Survival after transforma-
tion is dismal and usually less than 3 months. Cytogen-
etic and molecular techniques have elucidated some pa-
thophysiological mechanisms in CML, including the
Philadelphia translocation (Phb). Generally, standard
treatment of CML is not capable of eliminating the
Phb-positive clone and is therefore considered pallia-
tive, but not curative. Recently, therapies have been
devised aiming at the eradication of the Phb-positive
cell clone, a phenomenon designated Phb conversion.
We present a patient with a very unusual hematologic,
cytogenetic, and molecular course of CML after mild
first-line oral therapy only.
Case report
In August 1982, a 44-year-old man, known to have nephrolithia-
sis, presented to the urologist with pain in his flank. He had no
other complaints. Routine blood analysis revealed a leukocytosis.
Physical examination was normal; the spleen was not palpable. A
complete blood cell count revealed a hemoglobin of 8.8 mmol/l,
hematocrit of 0.45 l/l, platelet count of 145!109/l, white blood
cell count of 74!109/l with 1% myeloblasts, 1% promyelocytes,
17% myelocytes, 9% metamyelocytes, 16% bands, 38% seg-
mented neutrophils, 1% eosinophils, 3% basophils, 7% lympho-
cytes, and 7% monocytes. The value of lactate dehydrogenase
was 486 units/l (normal ~330 units/l). Further chemical examina-
tion of peripheral blood was normal. The leukocyte alkaline
phosphatase score was unexpectedly elevated (1095/100 cells); it
was absent at subsequent sampling. Slight hepatosplenomegaly
was found on technetium scintigraphy.
Bone marrow morphology showed a predominance of myelo-
poiesis (myelopoiesis :erythropoiesisp25 :1) and 5% myeloblasts.
Cytogenetic analysis of the bone marrow revealed the presence of
the Philadelphia chromosome in three of three metaphases, and
in one of these metaphases inversion of chromosome 7 was seen.
The diagnosis of Phb-positive chronic myelogenous leukemia in
chronic phase was made. The Sokal index was 0.8 [12].
Before treatment, peripheral stem cells were collected by con-
tinuous-flow leukapheresis and cryopreserved to be used as stem
cell rescue after intensive chemotherapy in case an accelerated or
blastic phase should occur [3]. Cytogenetic analysis of these he-
matopoietic progenitor cells showed the Philadelphia chromo-
some in 20 of 20 metaphases, as well as an additional inversion of
chromosome 7 in nine metaphases. Molecular analysis of these
hematopoietic progenitor cells was performed 7.5 years later and
revealed the presence of a hybrid breakpoint cluster region–
Abelson (BCR-ABL) messenger ribonucleic acid (mRNA) of the
b2a2 type. The method used has a sensitivity of detecting one
malignant cell derived from CML cell line k562 in 105 normal
cells.
The patient was treated with busulfan orally in gradually de-
creasing doses for 18 months with a total amount of 686 mg. The
peripheral blood cell count normalized after 6 months’ treatment
and remained normal during the follow-up period of 13 years af-
ter diagnosis. No aplastic phase occurred during or after busulfan
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Fig. 1 Therapy (a) and values of leukocytes (b) and platelets (c)
in peripheral blood during follow-up of patient
therapy (Fig. 1). Bone marrow morphology normalized 4.5 years
after diagnosis and remained normal up to the most recent sam-
pling, 11.5 years after diagnosis.
Sequential cytogenetic and molecular analysis of blood and
bone marrow samples collected 4–13 years after diagnosis showed
the almost complete conversion to a Phb-negative status (Table
1). Molecular analysis was performed using the Southern blot
technique in the beginning and later on reverse polymerase chain
reaction, as described before [2]. The detection of BCR-ABL
mRNA was only weakly positive in March 1992. Repeated testing
gave the same weakly positive result. This indicates that the num-
ber of BCR-ABL mRNA molecules was then at the detection lev-
el of the test, suggesting a low expression of the hybrid BCR-
ABL ongogene.
Discussion
Chronic myelogenous leukemia is a myeloproliferative
disorder associated with the Philadelphia chromosome
in more than 90% of patients. As a result of the Phila-
delphia translocation, the ABL oncogene is transferred
from chromosome 9 (band 34) onto the BCR gene on
chromosome 22 (band 11), where it encodes a chimeric
BCR-ABL mRNA transcript resulting in a BCR-ABL
fusion protein thought to be responsible for the leu-
kemic transformation [4].
In the literature several therapeutic options for pa-
tients with CML are recommended [1, 6–9, 13]. The
median survival of untreated patients is about 31
months. Symptoms of chronic-phase CML can usually
be controlled with oral busulfan or hydroxyurea, which
prolong the median survival to about 45 or 58 months,
respectively [9]. After a remission of CML has been
achieved with busulfan, the bone marrow usually re-
mains Phb positive, although a few Phb-negative remis-
sions have been reported following busulfan-induced
aplasia [8, 10]. Intensive combination chemotherapy
prolongs the median survival of chronic-phase CML
patients to about 57 months and results in cytogenetic
remission in up to a quarter of the patients. The median
survival of patients with chronic-phase CML is length-
ened to 72 months by treatment with interferon-alpha,
which leads to (partial) cytogenetic remission in 30% of
cases. At present, the only curative option is allogeneic
bone marrow transplantation, which is the treatment of
choice especially in young patients with CML in
chronic phase; it results in suppression of Phb-positive
cells in 100% and in a 3-year disease-free survival rate
of about 63%. A close correlation exists between disap-
pearance of Phb and hematologic remission.
The long-lasting, practically complete Phb conver-
sion of this patient is exceptional because it occurred
after a mild oral chemotherapy regimen without an epi-
sode of bone marrow aplasia. The calculated Sokal in-
dex of 0.8 indicates an intermediate relative risk of dy-
ing, which is more than one may expect in this patient
[12].
The Philadelphia translocation at diagnosis was cy-
togenetically and molecularly documented, in contrast
to other reports [5, 11]. Moreover, an additional aspe-
cific cytogenetic abnormality, the inversion of chromo-
some 7, was documented in bone marrow and apheresis
material at diagnosis. After treatment molecular studies
showed a weakly positive signal of BCR-ABL mRNA
at the detection level of the PCR technique on one oc-
casion. Apparently, the growth potential of the leu-
kemic clone has up to now been in equilibrium with
that of the normal hematopoietic progenitor cells. An
immunological suppression of the leukemic clone for at
least 3 years cannot be excluded. Similar observations
have been made only after allogeneic bone marrow
transplantation [14].
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Table 1 Sequential cytogenetic and molecular analyses of apheresis material, bone marrow, and peripheral blood of our patient (AM
apheresis material, BM bone marrow, PB peripheral blood, mBCR major breakpoint cluster region, SB Southern blot)
Date
(month/year)
Material Cytogenetic analysis Molecular analysis
Number of
metaphases
Karyotype Technique Result
(breakpoint)
09/1982 BM 3 46,xy,t(9;22) [2]/
46,xy,t(9;22),inv(7) [1]
AM 20 46,xy,t(9;22) [11]/
46,xy,t(9;22),inv(7) [9]
AM SB Positive (mBCR)
AM RT-PCR Positive (b2a2)
11/1986 BM 6 46,xy
01/1987 BM 38 46,xy
09/1989 BM RT-PCR Negative
03/1992 BM 21 46,xy
BM RT-PCR Weakly pos (b2a2)
PB RT-PCR Negative
02/1994 BM RT-PCR Negative
PB RT-PCR Negative
02/1995 PB RT-PCR Negative
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